e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 34

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab

James L. Alexander; Hajir Ibraheim; Bhavisha P. Sheth; Jessica Little; Muhammad Khan; Camellia Richards; Nikki Hunter; Dharmisha Chauhan · 2021 · Journal for ImmunoTherapy of Cancer

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

INTRODUCTION: Immune checkpoint inhibitors (CPIs) have changed the treatment landscape for many cancers, but also cause severe inflammatory side effects including enterocolitis. CPI-induced enterocolitis is treated empirically with corticosteroids, and infliximab (IFX) is used in corticosteroid-refractory cases. However, robust outcome data for these patients are scarce. METHODS: We conducted a multicenter (six cancer centers), cohort study of outcomes in patients treated with IFX for corticosteroid-refractory CPI-induced enterocolitis between 2007 and 2020. The primary outcome was corticoster

Abstract by James L. Alexander; Hajir Ibraheim; Bhavisha P. Sheth; Jessica Little; Muhammad Khan; Camellia Richards; Nikki Hunter; Dharmisha Chauhan, Journal for ImmunoTherapy of Cancer (2021) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1136/jitc-2021-002742